SavedAdd your journal

Journals / Psikiyatride Güncel Yaklaşımlar / 2015 / Cilt: 7 - Sayı: 3

Psychostimulants in the Treatment of Depressive Disorders

Depresif Bozuklukların Tedavisinde Psikostimulanlar

Okan EKİNCİ
Aslı ERKAN EKİNCİ
Selahattin BÖLEK
Pages
304–18
Publication Date
2015-07-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review study, we reviewed the available literature on the efficacy of these agents for treatment of refractory unipolar and bipolar depression.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Despite antidepressant therapy of appropriate trial duration and dose optimization, 50-60% of depressed patients have an adequate treatment response, whereas only 35-40% achieve remission.
📊
Key Findings & Data:Psychostimulants have been suggested as potential candidates to promote acceleration of response and to alleviate residual symptoms of depression.
💡
Conclusion & Impact:In this review study, we reviewed the available literature on the efficacy of these agents for treatment of refractory unipolar and bipolar depression.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Depresyon · metilfenidat · modafinil

Abstract

Despite antidepressant therapy of appropriate trial duration and dose optimization, 50-60% of depressed patients have an adequate treatment response, whereas only 35-40% achieve remission. Psychostimulants have been suggested as potential candidates to promote acceleration of response and to alleviate residual symptoms of depression. Nowadays, clinicians often consider the off-label use of stimulants or stimulant alternatives as adjunctive antidepressants. In this review study, we reviewed the available literature on the efficacy of these agents for treatment of refractory unipolar and bipolar depression.

Özet

Uygun doz ve sürede antidepresan tedaviye rağmen depresif hastaların yaklaşık %50-60‘ında yeterli tedavi cevabı sağlanırken, sadece %35-40’ında remisyona ulaşılır. Psikostimulanlar depresyon tedavisinde rezidüel belirtilerin iyileştirilmesi ve tedavi cevabını hızlandırmak için aday ilaçlardandır. Klinisyenler günümüzde onaydışı olarak psikotimulanların ve alternatiflerini depresyonda güçlendirici tedavi olarak kullanmaktadırlar. Bu yazıda psikostimulan ajanların bipolar ve unipolar depresyonda etkinliği gözden geçirilmiştir.

🔖

Cite This Article

EKİNCİ, O., EKİNCİ, A. E., BÖLEK, S. (2015). Psychostimulants in the Treatment of Depressive Disorders. Psikiyatride Güncel Yaklaşımlar, Cilt: 7 - Sayı: 3, 304–18. https://ajindex.com/articles/229979

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M et al. (2011) Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety, 28:297-302.
  2. Anders T, Sharfstein S (2006) ADHD drugs and cardiovascular risk. N Engl J Med, 354;2296-2298.
  3. Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA (2010) Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry, 71:1363-1370.
  4. Carlson PJ, Merlock MC, Suppes T (2004) Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord, 6:416-420.
  5. Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH (2005) Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry, 66:1234-1238.
  6. DeBattista C, Doghramji K, Menza MA (2003) Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double- blind, placebo-controlled study. J Clin Psychiatry, 64:1057-1064.
  7. DeBattista C, Lembke A, Solvason HB (2004) A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol, 24:87-90.
  8. Durukan I, Erdem M, Kara K, Karaman D (2013) Psikostimülan ilaçların gelişen beyin üzerindeki etkileri. Psikiyatride Güncel Yaklaşımlar, 5:528-539.
  9. El-Mallakh RS (2000) An open study of methylphenidate in bipolar depression. Bipolar Disord, 2:56-59.
  10. Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ (2007) Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry, 19:153-159.
  11. Fava M, Thase ME, DeBattista C (2005) A multicenter, placebocontrolled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry, 66: 85-93.
  12. Fawcett J, Kravitz HM, Zajecka JM (1991) CNS stimulant potentiation of monoamine oxidase inhibitors in treatment refractory depression. J Clin Psychopharmacol, 11:127-132
  13. Femandez F, Adams F, Holmes VF (1987) Methylphenidate for depressive disorders in cancer patients. Psychosomatics, 28:455 FDA [Food and Drug Administration] (